Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.
The Planning Committee at Cambridge City Council yesterday (7 Feb) voted in favour of the multi-million-pound regeneration for the shopping centre, which will be converted into laboratory and office space for life science and tech companies. The western end of the centre will be retained and transformed into a more attractive destination for local shoppers.
The…
Barcelona and Nottingham, February 8th, 2024
Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics,
and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk
early-stage breast cancer patients, have signed an exclusive agreement to start offering the MAF
Test® as a service in United Kingdom and Ireland. The MAF Test® predicts the prognosis of breast
cancer patients and helps oncologists to identify those patients who may be able to prevent
recurrence and benefit from adjuvant treatment with bisphosphonates, which…
Read February eNews: Where to find Your Life Science Connections, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Moving Forward Together
✅ Is it Rocket Science?
✅ Use One Nucleus' High Profile Initiatives to Reach Your Audience
✅ Narrowing the Odds on Success
✅ Nominate Your Life Sciences Inspiration of the Year Award 2024
✅ Upcoming Events for Your Diary
New NGS Laboratory opens its doors for genomics researchers.
Azenta Life Sciences will officially open its new GENEWIZ Multiomics and Synthesis Solutions laboratory in Oxford, UK in March 2024. As a global provider of R&D genomics services, Azenta leads the way in providing superior data quality with unparalleled technical support to enable researchers around the world to advance their scientific discoveries faster than ever before.
Dr Ginger Zhou, Senior Vice President and General Manager for GENEWIZ Multiomics & Synthesis Solutions said, “The opening of our genomics lab in Oxford…
1 February 2024 - Cambridge, UK - Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development. The appointment is part of a planned succession process, with co-founder Dr John McCafferty transitioning from Chief Executive Officer to Chief Technology Officer after having co-founded Maxion, raised $16 million in initial…
29 February 2024 | The Garden Room, St John’s Innovation Centre, Cambridge
It’s never too early to start planning your business exit. Business exit strategy experts Yellowyoyo have teamed up with Innovate UK EDGE to deliver an essential event for founders that will set you on the road to maximising value, whether you plan to exit in five years or fifty years. Do you plan to sell your business, pass it to your chosen successor, merge with another company or stay on in a new role? Whatever your preferred exit, the time to start preparing is now.
The agenda will include valuable group…
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as US Director of Sales. In his new role, Joe will lead the expansion of the Company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.
Following several key senior appointments in…
• Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister launch Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC).
• Shadow Ministers take part in roundtable discussion with key industry figures including AstraZeneca, GSK, BioIndustry Association (BIA) and Stevenage Bioscience Catalyst and its high growth companies to hear at first hand the opportunities and challenges facing the sector and the vibrant strength of the UK’s life science ecosystem.
Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister, today launched Labour’s Life…
Source Genomics Expands Sequencing Portfolio with First UK Commercial Service on the Element Biosciences AVITI™ System
Cambridge, UK, 31 January 2024: Source Genomics, a part of the Source BioScience Group, today announced their genomic laboratory expansion by adding an Element Biosciences AVITI™ System to its fleet of sequencers.
As the demand for genomic sequencing increases in the UK, Source Genomics is expanding its offering to meet the escalating needs of the life science research market. The incorporation of Element Biosciences AVITI™ System is set to transform the landscape of genomic…
Pioneer Group, a company combining laboratory development and operation with venture building, has teamed up with CPI, the independent deep tech innovation organisation, to launch a Golden Ticket programme for innovations in planetary health.
The 2024 Golden Ticket Programme is open to hydrogen and climate technology companies that are innovating solutions to some of the biggest challenges we face, with funding for the initiative coming from the Hydrogen Innovation Initiative (HII) – a trusted group of organisations working with industry, government, and academia to create an investible,…